CXCR2 and inflammatory bowel disease: In patients with IBD, the degree of neutrophil infiltration and the reappearance of neutrophils in the intestinal mucosa are thought to represent the disease activity and clinical remission, respectively.34,35 During the whole process of DSS modeling, inhibiting neutrophil infiltration daily by blocking CXCR2, a common ligand for neutrophil functionality, was reported to decrease proinflammatory cytokine production and reduced intestinal damages36.